These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 32449440)
1. Tedizolid (torezolid) for the treatment of complicated skin and skin structure infections. Carena AA; Stryjewski ME Expert Rev Clin Pharmacol; 2020 Jun; 13(6):577-592. PubMed ID: 32449440 [TBL] [Abstract][Full Text] [Related]
2. Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity Infections Joseph WS; Culshaw D; Anuskiewicz S; De Anda C; Prokocimer P J Am Podiatr Med Assoc; 2017 Jul; 107(4):264-271. PubMed ID: 27533787 [TBL] [Abstract][Full Text] [Related]
3. Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic. Burdette SD; Trotman R Clin Infect Dis; 2015 Oct; 61(8):1315-21. PubMed ID: 26105167 [TBL] [Abstract][Full Text] [Related]
4. Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA. McCool R; Gould IM; Eales J; Barata T; Arber M; Fleetwood K; Glanville J; Kauf TL BMC Infect Dis; 2017 Jan; 17(1):39. PubMed ID: 28061827 [TBL] [Abstract][Full Text] [Related]
5. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens. Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021 [TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections. McBride D; Krekel T; Hsueh K; Durkin MJ Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):331-337. PubMed ID: 28140693 [TBL] [Abstract][Full Text] [Related]
7. An evaluation of tedizolid for the treatment of MRSA infections. Hall RG; Smith WJ; Putnam WC; Pass SE Expert Opin Pharmacother; 2018 Sep; 19(13):1489-1494. PubMed ID: 30200779 [TBL] [Abstract][Full Text] [Related]
8. Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections: pooled data from phase 3 clinical trials. Corey R; Moran G; Goering R; Bensaci M; Sandison T; De Anda C; Prokocimer P Diagn Microbiol Infect Dis; 2019 Jul; 94(3):277-286. PubMed ID: 30940414 [TBL] [Abstract][Full Text] [Related]
9. Antibacterial Activity of Tedizolid, a Novel Oxazolidinone Against Methicillin-Resistant Hasannejad-Bibalan M; Mojtahedi A; Biglari H; Halaji M; Sedigh Ebrahim-Saraie H Microb Drug Resist; 2019 Nov; 25(9):1330-1337. PubMed ID: 31290721 [TBL] [Abstract][Full Text] [Related]
10. In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections. Prokocimer P; Bien P; Deanda C; Pillar CM; Bartizal K Antimicrob Agents Chemother; 2012 Sep; 56(9):4608-13. PubMed ID: 22687509 [TBL] [Abstract][Full Text] [Related]
11. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones. Douros A; Grabowski K; Stahlmann R Expert Opin Drug Metab Toxicol; 2015; 11(12):1849-59. PubMed ID: 26457865 [TBL] [Abstract][Full Text] [Related]
12. Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones. Cattaneo D; Alffenaar JW; Neely M Expert Opin Drug Metab Toxicol; 2016 May; 12(5):533-44. PubMed ID: 26982718 [TBL] [Abstract][Full Text] [Related]
13. Tedizolid phosphate for the treatment of acute bacterial skin and skin structure infections. Gras J Drugs Today (Barc); 2014 Nov; 50(11):729-37. PubMed ID: 25525633 [TBL] [Abstract][Full Text] [Related]
14. Tedizolid population pharmacokinetics, exposure response, and target attainment. Flanagan S; Passarell J; Lu Q; Fiedler-Kelly J; Ludwig E; Prokocimer P Antimicrob Agents Chemother; 2014 Nov; 58(11):6462-70. PubMed ID: 25136028 [TBL] [Abstract][Full Text] [Related]
15. Platelet profile in patients with acute bacterial skin and skin structure infections receiving tedizolid or linezolid: findings from the Phase 3 ESTABLISH clinical trials. Lodise TP; Fang E; Minassian SL; Prokocimer PG Antimicrob Agents Chemother; 2014 Dec; 58(12):7198-204. PubMed ID: 25246392 [TBL] [Abstract][Full Text] [Related]
16. Tedizolid: a new oxazolidinone antimicrobial. Kisgen JJ; Mansour H; Unger NR; Childs LM Am J Health Syst Pharm; 2014 Apr; 71(8):621-33. PubMed ID: 24688035 [TBL] [Abstract][Full Text] [Related]
17. The safety of treatment options for acute bacterial skin and skin structure infections. Bassetti M; Peghin M; Castaldo N; Giacobbe DR Expert Opin Drug Saf; 2019 Aug; 18(8):635-650. PubMed ID: 31106600 [TBL] [Abstract][Full Text] [Related]
18. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance. Rybak JM; Marx K; Martin CA Pharmacotherapy; 2014 Nov; 34(11):1198-208. PubMed ID: 25266820 [TBL] [Abstract][Full Text] [Related]
19. Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections. Ferrández O; Urbina O; Grau S Drug Des Devel Ther; 2017; 11():65-82. PubMed ID: 28053508 [TBL] [Abstract][Full Text] [Related]
20. Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model. Keel RA; Tessier PR; Crandon JL; Nicolau DP Antimicrob Agents Chemother; 2012 Aug; 56(8):4403-7. PubMed ID: 22687504 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]